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Background: Since 2006, routine HPV vaccination has been recommended for females aged 11–12 in the US.
However not much is known about the extent of and factors associated with HPV vaccination after the ages
of 11–12.
Methods: Provider-veriﬁed data on 8710 females aged 13–17 were analyzed from the 2013 NIS-Teen survey.
2013 Data was utilized since it was the ﬁrst year one can fully evaluate the age at vaccination through age 17
for females who could receive the HPV vaccine at age 11.
Results: Among HPV vaccinated females who were 17 in 2013, 47% (95% CI¼43–50%) received their ﬁrst dose
after age 12, and 24% (95% CI¼21–26%) received their ﬁrst dose after age 14. The HPV vaccine was more likely
to be initiated later than the meningococcal and Tdap vaccines (po0.05), and later HPV vaccine initiation was
more common among those having a more highly educated mother and those not receiving a check-up/well
visit between the ages of 11 and 12 in adjusted analyses (p-valueso0.05). Females initiating the HPV vaccine
late were more likely to not receive three doses (RR¼1.90, 95% CI¼1.76–2.04).
Conclusions: HPV vaccination is commonly initiated after the age of 12 in the US, which could limit the vac-
cine's population-level effectiveness.
Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Human papillomavirus (HPV) is a common sexually transmitted
infection that can lead to cervical, oropharyngeal, and other anogenital
cancers as well as genital warts [1]. Prophylactic HPV vaccines have
demonstrated nearly 100% efﬁcacy against infectionwith certain high-
risk HPV types among individuals not previously exposed to HPV [2,3].
However, the HPV vaccines are most effective when administered
prior to HPV exposure, as these vaccines do not have a therapeutic
effect on active HPV infections [4].
In 2006, the US Advisory Committee on Immunization Practices
(ACIP) recommended routine HPV vaccination for females aged 11–12
[5,6]. “Catch-up” vaccination was also recommended for females ages
13–26 who have not been vaccinated previously [5]. As of 2013, 57% of
females aged 13–17 in the US had received at least one dose of an HPV
vaccine, and 38% received all three doses of the HPV vaccine as
recommended [7].
Multiple demographic, cognitive, and contextual factors have been
found to be associated with HPV vaccine uptake [7–11], but much less
is known about factors related to the age at vaccine initiation. The ageaccess article under the CC BY-NC
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chler).at HPV vaccine initiation is important given that HPV infection and its
related sequelae can often occur at young ages with a North American
study suggesting approximately one third of unvaccinated females
were HPV infected in their teen years [12] and another suggesting that
cervical dysplasia and genital warts can often occur in females aged
14–17 years [13].
Data are now available to examine the age at vaccination initiation
through age 17 among females who were between 9 and 11 years old
when the HPV vaccine was ﬁrst recommended and available in 2006–
2007. Our aims in the current study were to describe the age-speciﬁc
prevalence of HPV vaccine initiation and identify factors that may
differentiate females initiating the HPV vaccine during the recom-
mended ages of 11–12 from females initiating the vaccine after age 12.2. Methods
2.1. Study population and design
This study utilized the publically available de-identiﬁed
National Immunization Survey-Teen (NIS-teen) surveys from
2010 to 2013 conducted by the US Center for Diseases Control's
(CDC) National Center for Immunization and Respiratory Diseases
[7]. NIS-Teen sampled parents or guardians of eligible teens, aged
13–17 at the time of the survey, from all 50 states and the District-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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sample of landline and starting in 2011, cellular telephones [7].
When approval was granted by the parent or guardian, ques-
tionnaires regarding vaccination history including the HPV,
meningococcal, and Tetanus, Diphtheria, and Pertussis (Tdap)
vaccines were also sent to the teen's providers. Provider-reported
immunization histories were synthesized with other available
demographic and behavioral information and samples were
weighted to estimate the general US population, as previously
described [14,15].
Our main analyses examined the age of HPV vaccine initiation
among the 8710 females from the US who were in NIS-teen 2013
and had provider-reported immunization histories. Some of these
analyses were restricted to the 5269 females who received at least
one dose of the HPV vaccine. In addition, we focused some ana-
lyses on the 1509 females who were 17 years of age in NIS-teen
2013. The Gardasil HPV4 vaccine was approved by the US Federal
Drug Administration (FDA) and recommended by the Center of
Disease Control (CDC)'s Advisory committee on Immunization
Practices (ACIP) in June of 2006 and was available on the market in
the subsequent months [5,6]. The household interviews for the
2013 NIS-teen survey began on January 10, 2013 and ended on
February 13, 2014 [15]. Thus, females who were 17 years of age in
the NIS-teen 2013 survey were born between January 1995 and
February 1997. These individuals were between the ages of 9 and
11 years old when the vaccine was recommended and available,
and are thus the oldest cohort that could have been vaccinated at
age 11 in accordance with recommendations for routine HPV
vaccination.
In a sub-analysis that examined whether the age at HPV vac-
cine initiation may be changing over time, we also utilized NIS-
teen survey data from 2010 to 2012 to evaluate the ages at HPV
vaccine initiation among the 5465 females who were older than
the routine recommended ages when the HPV vaccine was
approved (i.e. those born between 1992 and 1995 who were 17 in
NIS-teen 2010–2012). Additionally, we examined the age of vac-
cine initiation by age 15 in the 5079 females who were at least 15
in NIS-teen 2013 (i.e. those born in 1995–1998) in NIS-teen 2013.
HPV vaccination was not routinely recommended for US males
until 2011 [16], so they were therefore not included in any
analyses.
2.2. Measures
This study's primary outcome of interest was age when
receiving the ﬁrst dose of the HPV vaccine (either Gardasil (HPV4)
or Cervarix (HPV2)). We also examined the ages when receiving
the Tdap and meningococcal vaccines, the two other vaccines that
are routinely recommended for adolescents aged 11–12, as sec-
ondary outcomes. The routine recommendations for the menin-
gococcal and Tdap vaccines were made in the spring of 2005
[17,18], one year prior to the HPV vaccine recommendation. Only
vaccine doses received prior to the date of the parental interview
were included. While the adolescents’ exact ages in days at the
time of their vaccinations and their age in years at the time of the
survey were included in the NIS-teen database, the participants’
exact birthdays and date of each survey were not included.
Because individuals’ exact ages when the HPV vaccine was FDA
approved were unknown, age ranges for each cohort of partici-
pants when the HPV vaccine was approved are included in this
manuscript.
Demographic and behavioral measures collected through the
parental interview in the NIS-teen were included in this analysis
[15]. Healthcare access was categorized as either: private insur-
ance, federal Vaccines for Children (VFC), or other coverage, as
previously described [8]. The VFC program covers all femalesunder 19 who are eligible for Medicaid, uninsured, were an
American Indian/Alaska Native or attended a federally qualiﬁed
health center [19]. Individuals who had the State Children's Health
Insurance Program (CHIP) coverage, but not Medicaid were cate-
gorized as having “other” coverage.2.3. Statistical analyses
Probability sampling weights were utilized in all analyses
through STATA 13 svy commands (StataCorp, College Station, TX)
to obtain nationally representative estimates. The weights account
for the multi-state stratiﬁed sampling design and differential
response rates [15]. The HPV vaccination status and age of initia-
tion was calculated for the 8710 females aged 13–17 in NIS-teen
2013. Potential factors associated with later HPV vaccine initiation
(after age 12) among the 5269 HPV vaccinated females aged 13–17
in NIS-teen 2013 were evaluated through weighted Poisson
regression with robust error variances [20]. This method was uti-
lized instead of weighted logistic regression given the high pre-
valence of the outcome (vaccination after age 12).
Three different forms of multivariate adjustment were per-
formed. We performed individual models for each covariate of
interest ﬁrst adjusting for only for age, then adjusting for age and
further demographic factors, and ﬁnally for age, demographic
factors and other exposures signiﬁcant in prior age-adjusted
modeling (location, check-up visit). Delayed Meningococcal/Tdap
vaccine initiation was not included in this model since it was not
considered an exposure; rather it was considered a separate out-
come that may be correlated with late HPV vaccine initiation.
Adjusted relative risks (RRs) and 95% conﬁdence intervals (95%
CIs) were reported for each of the three models. We also examined
whether females received all three doses of the HPV vaccine,
restricting to individuals who were followed at least 24 weeks
following their ﬁrst HPV vaccine dose [15]. Chi-square tests and
linear p-trends were estimated using continuous values for ordinal
or continuous variables, when available. All statistical tests were
two-sided and considered signiﬁcant at an α¼0.05 level.3. Results
3.1. Age of vaccination for females born in 1995–1996
Among females in the United States who were 17 in 2013, 62%
(95% CI¼58–67%) received at least one dose of the HPV vaccine.
Although these females born in 1995–1996 were between 9 and 11
years of age when the HPV vaccine was recommended and became
available, close to half of those vaccinated received their ﬁrst HPV
vaccine dose after the recommended ages of 11–12 (47%, 95%
CI¼43–50%), and nearly a quarter (24%, 95% CI¼21–26%) received
their ﬁrst dose between the ages of 15–17 (Fig. 1).
The HPV vaccine was more likely to be initiated at older ages
than the meningococcal and the Tdap vaccines among females
aged 17 in 2013 (Fig. 1). Among those vaccinated, the HPV vaccine
was more commonly initiated after age 12 (47% vs. 41% (menin-
gococcal), p¼0.02; 47% vs. 30% (Tdap), po0.001; Fig. 1), and after
age 14 (24% vs. 12% (meningococcal), po0.001; 24% vs. 9% (Tdap),
po0.001; Fig. 1), than the other vaccines. Most HPV vaccinated
females were vaccinated for both Tdap and Meningococcal disease
(90%), while HPV vaccination was less common among individuals
who received either a Meningococcal vaccine (67%) or the Tdap
vaccine (61%).
Fig. 1. Vaccination status and age of vaccine initiation among 1509 females aged 17
in NIS-teen 2013*. Overall, 62% of females recived at least one HPV vaccine dose,
79% received at least one meningococcal vaccine dose, and 90% recived at least one
Tdap vaccine dose. P^ercent receiving the vaccine between the ages of 9 and 12
among vaccinated females. *The ACIP recommends routine vaccination with the
HPV, Meningococcal, and Tdap vaccines between the ages of 11 and 12.
Fig. 2. Vaccination status and age of vaccine initiation by age 15 among 5079
females aged 15–17 in NIS-teen 2013. #This analysis was restricted to 5079 females
who were 15 or older at the time of the survey. This analysis excluded vaccinations
after age 14 given that many females born in more recent years (1996–1998) were
not yet 16–17 at the time of this survey. P^ercent receiving the HPV vaccine between
the ages of 9 to 12 among the 2634 females born between 1995 and 1998 and HPV
vaccinated prior to age 15. *As the NIS-2013 survey was conducted between Jan-
uary 2013 and February 2014, years of birth ranged two years in each grouping (i.e.
those aged 17 at the time of the survey were born between January 1995 and
February 1997 but is classiﬁed as 1995-6 in the ﬁgure above).
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Most females who were 17 years of age in previous versions of
NIS-teen (2008–2012) were born between 1992 and 1995 and
were 12 or older when the HPV vaccine was recommended and
became available. Thus the vast majority of these individuals
received the vaccine after age 12 (Supplementary Fig. 1).
When restricting again to the 8710 females in NIS-teen 2013,
we observed that a higher percentage of females born from 1995
to 2000 initiated HPV vaccination between the ages of 11–12 and
between the ages of 13–14 in more recent years (Supplementary
Fig. 2). HPV vaccine uptake by age 13 increased from 33% for those
born in 1995–1996 to 44% for those born in 1999–2000 (p-
trendo0.001), and the HPV vaccine uptake between the ages of
13–14 non-signiﬁcantly increased from 14% for those born in
1995–1996 to 20% in the youngest eligible group born in 1997–
1998 (p-trend¼0.09; Supplementary Fig. 2). However, given the
increases in both age groups, the percent of HPV vaccinated
females receiving the vaccine prior to age 13 did not increase in
analyses restricted to relevant populations born from 1995 to 1998
(Fig. 2). Indeed, when restricting to 2634 HPV vaccinated females
who were 15 or older at the time of the survey, the percent
receiving the vaccine at the ages of 11–12 modestly declined from
70% in those born in 1995–1996 to 62% and 63% for those born in
1996–1997 and 1997–1998 (p-valueso0.01, Fig. 2).
3.3. Factors related to later HPV vaccine initiation
HPV vaccinated females were considerably more likely to
initiate the HPV vaccine after age 12 if they also initiated the
meningococcal or Tdap vaccine late (71% vs. 25%, age-adjusted
RR¼2.76, 95% CI¼2.39–3.19; Table 1). In fact, the individuals who
initiated both the meningococcal and Tdap vaccines after age 12
were the most likely to initiate HPV vaccine after age 12 (86%,
adjusted RR¼3.24, 95% CI¼2.81–3.73).
Among the demographic factors examined, later HPV vaccine
initiation (after age 12) was shown to be more common among
females with more educated mothers (41% vs. 30%, po0.05) and a
higher family income (41% vs. 31%, po0.05, Table 1) in age-
adjusted analyses. In addition, not receiving a check-up or well
visit at ages 11–12 was associated with an increased likelihood of
later HPV vaccine initiation (RR¼1.46, 95% CI¼1.16–1.84), how-
ever the vast majority of HPV vaccinated females received a check-
up or well-visit between the ages of 11 and 12 (95%). The percentof females initiating the HPV vaccine late was similar across race/
ethnicity, health insurance status, type of provider, and whether a
physician/healthcare provider ever recommended the vaccine (p-
values40.05, Table 1). However, HPV vaccination was less likely to
be initiated late among HPV vaccinated females in the southern US
compared to those in the northeast (32% vs. 42%, po0.05, Table 1).
Even in controlled multivariate analysis, later HPV vaccine
initiation was more likely among females with more educated
mothers and those who did not have well child or check-up visits
between the ages of 11 and 12 (p-trend¼0.01 and adjusted
RR¼1.58, 95% CI¼1.28–1.96, respectively; Table 1). In addition,
HPV vaccinated individuals living in the southern US remained
less likely to initiate the HPV vaccine late than HPV vaccinated
females from the northeast (adjusted RR¼0.78, 95% CI¼0.67–
0.92). Higher family income and race/ethnicity were not associated
with later HPV vaccine initiation after adjustment.
3.4. HPV vaccine dose completion by age of vaccine initiation
Females who initiated the HPV vaccine after age 12 were also
almost twice as likely to not complete all three doses of the vac-
cine compared to those who received the vaccine between the
ages of 11 and 12 (age-adjusted RR¼1.90, 95% CI¼1.76–2.04,
Table 2). Among HPV vaccinated females who received all three
HPV vaccine doses, 26% received their ﬁrst dose after the age of 12.
This prevalence of later initiation was considerably lower than the
prevalence in women receiving only two (44%) or one doses (46%)
(P-valueso0.001, Table 2).4. Discussion
This study provides evidence that HPV vaccination in the US is
commonly initiated after the recommended ages of 11–12 for
routine vaccination and the percentage of HPV-vaccinated females
initiating after age 12 has not yet declined over time. Compared to
other recommended vaccines, HPV vaccination initiation is more
commonly delayed until older ages and this may limit the
population-level effectiveness of the HPV vaccine in the US.
Individuals receiving the HPV vaccine at older ages may obtain
less protection from the vaccine depending on the age of their
sexual debut. A previous study suggested that over a quarter of
females acquired at least one HPV type within the ﬁrst year of
their sexual debut [21] and a third of US females aged 14–19 had a
Table 1
Risk factors for later HPV Vaccine initiation among 5269 females in NIS-teen 2013 receiving at least one dose of the HPV vaccine.




Model 1a,b demo.-adj. RR
(95% CI)
Model 2a,c further-adj. RR
(95% CI)
Education level of mother
HS grad or less 1619 29.5% REF REF REF
Some college 1382 41.5% 1.35 (1.12–1.63) 1.33 (1.10–1.62) 1.37 (1.13–1.66)
College grad 2268 40.0% 1.33 (1.13–1.56) 1.25 (1.03–1.52) 1.27 (1.05–1.54)
p-Trend 0.003 0.02 0.01
Race/ethnicity
Caucasian 3201 38.5% REF REF REF
Hispanic 891 32.8% 0.88 (0.72–1.08) 1.00 (0.82–1.22) 1.04 (0.86–1.27)
Non-hispanic black 520 32.8% 0.84 (0.68–1.04) 0.89 (0.72–1.10) 0.91 (0.73–1.12)
Non-hispanic other 657 35.1% 0.91 (0.70–1.16) 0.94 (0.73–1.20) 0.83 (0.64–1.08)
Family income
Below poverty 1049 31.1% REF REF REF
Above poverty, r$75 K/year 1835 35.2% 1.06 (0.87–1.30) 0.98 (0.79–1.21) 0.99 (0.80–1.23)
Above poverty, 4$75 K/year 2261 41.4% 1.25 (1.03–1.52) 1.08 (0.85–1.38) 1.06 (0.82–1.35)
Unknown 124 24.7% 0.73 (0.44–1.19) 0.69 (0.43–1.11) 0.65 (0.40–1.04)
p-Trend 0.02 0.35 0.49
Well-child/check-up between ages of 11 and 12
Yes 4258 38.3% REF REF
No 245 55.6% 1.46 (1.16–1.84) 1.58 (1.28–1.96)
Don't know 130 49.8% 1.34 (0.99–1.83) 1.41 (1.04–1.92)
Location
Northeast 1161 42.1% REF REF
Midwest 1116 39.1% 0.96 (0.83–1.10) 0.95 (0.82–1.10)
South 1612 32.1% 0.79 (0.67–0.92) 0.78 (0.67–0.92)
West 1203 34.4% 0.84 (0.68–1.05) 0.85 (0.69–1.05)
Health insurance
Private 2733 39.2% REF
VFC eligible 1316 33.4% 0.87 (0.74–1.03)
Other 899 34.6% 0.90 (0.74–1.11)
Facility of provider
Public 736 38.0% REF
Hospital 536 31.0% 0.79 (0.57–1.11)
Private 2365 37.7% 0.98 (0.79–1.22)
All STD/school/teen clinic 132 25.1% 0.69 (0.42–1.13)
Mixed/unknown 1500 34.3% 0.89 (0.70–1.13)
Delayed Meningococcal or Tdap vaccine initiation
No – vaccinated both 11–12 3506 24.7% REF
Yes – one or both 888 71.2% 2.76 (2.39–3.19)
Language
English 4843 37.1% REF
Spanish 381 28.4% 0.78 (0.57–1.05)
Other 45 47.4% 1.25 (0.82–1.91)
Physician/HC recommendation for vaccination
Yes 4200 37.4% REF
No 780 31.0% 0.87 (0.70–1.09)
Don't know 260 37.1% 1.01 (0.75–1.36)
a Survey weighted.
b Adjusted for age, education status of mother, family income, and race/ethnicity.
c Adjusted for age, education status of mother, family income, and race/ethnicity, location, and well-child/check-up between ages of 11 and 12.
Table 2
Number of HPV doses by age of HPV vaccine initiation among 5269 HPV vaccinated
females within NIS-teen 2013a.
Demographic N (%) % Receiving vaccine
after the age of 12b
Age adjusted
RR (95%CI)b,c
Number of HPV doses
3 3466 (71.2%) 26.1% REF
2 786 (16.2%) 43.8% 1.91 (1.75–2.09)b
1 276 (12.7%) 45.6% 1.88 (1.71–2.06)b
p-Trend o0.001
a Restricted to individuals who were followed at least 24 months following
their ﬁrst HPV vaccine dose.
b Survey weighted.
c 3 vs. 2/1 doses: RR¼1.90 (95% CI¼1.76–2.04).
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other studies report that approximately half of US teens initiate
sexual behavior prior to or at the age of 17 [22,23]. Thus given that
almost half of vaccinated females initiated the HPV vaccine
between the ages of 13 and 17, many of them may not have
obtained full protection from the vaccine.
Not only did we observe that later HPV vaccine initiation was
common, but our analysis suggests that the percentage of HPV
vaccinated females initiating the vaccine at older ages has not
declined in more recent years. Another recent analysis of 2008–
2012 NIS-Teen data reported that the mean age at HPV vaccination
is declining in more recent years [24]. However counter to this
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1994 or earlier who were already 13 or older when the HPV vac-
cine was approved. Therefore, this previously reported decline in
the mean age at HPV vaccination between 2010 and 2013 is likely
due to the fact that a larger proportion of included females were
eligible to be vaccinated at ages 11–12 each subsequent year. Our
analysis differs in that we limited our analysis to those females
who were eligible to be HPV vaccinated at age 11.
Our study suggests that the previously observed increase in
HPV vaccine uptake in more recent cohorts [7,25] is driven by both
an increased uptake prior to age 13 and an increased uptake
during the ages of 13 and above. In other words, HPV vaccine
uptake appears to be increasing in cohorts born more recently, but
a sizeable percentage of these cohorts continue to be receiving the
vaccine at older ages (after age 12). Continued follow-up of more
recent cohorts born after 1997 are necessary to determine whe-
ther later HPV vaccine initiation continues to be common.
Factors associated with later HPV vaccination initiation in this
study appear to be fairly similar to those related to reduced HPV
vaccine uptake [7–11]. For example, we found that having a higher
maternal education and lack of healthcare utilization were asso-
ciated with later initiation, and both of these factors have been
previously related to reduced HPV vaccination uptake [7–11].
Additionally, we found that vaccine initiation occurs at older ages
among HPV vaccinated females compared to Tdap and meningo-
coccal vaccinated females. Previous studies have suggested lower
uptake of the HPV vaccine than the Tdap and meningococcal
vaccines [7]. This coupled with our observation that later menin-
gococcal/Tdap initiation is strongly associated with later HPV
vaccine initiation suggests that there are some females delaying
initiation of multiple vaccines while others may just be delaying
initiation of the HPV vaccine.
This study also found that the age of HPV vaccine initiation is
comparable across race/ethnicity, which mirrors the ﬁnding that
HPV vaccine uptake is fairly similar by race/ethnicity [7], although
uptake may be modestly higher among Hispanic females [7,9].
There were some differences between factors for HPV vaccine
uptake and age of vaccine initiation. Previous analyses of the NIS-
Teen data have found females living in the US south to be the least
likely to initiate the HPV vaccine [26]. Our results suggest that the
limited number of southern females who do initiate the vaccine
are more likely to receive it prior to age 13.
Our study also found that females initiating the HPV vaccine at
older ages were about two times less likely to receive all three
recommended doses than those vaccinated at age 11–12. Non-
completion of the HPV vaccine series is common in the US, as over
a quarter of HPV vaccinated females do not receive all three doses
[7]. A recent post-hoc analysis of a randomized control trial found
that the HPV vaccine efﬁcacy is similar between one, two, and
three doses [27], and that antibody titers are similar in those
receiving two or three doses [28]. However, further evaluation in a
formal randomized clinical trial is necessary. Females who initi-
ated the vaccine later are at a higher risk of having a prevalent HPV
infection by the time of vaccination, and thus our study suggests
that this factor could confound the relationship between the
number of doses and HPV vaccine effectiveness in observational
studies. Future observational studies examining the HPV vaccine
effectiveness of fewer doses should adjust for age at the time of
vaccination and other potential confounders such as number of
sexual partners prior to vaccination if available.
This is one ﬁrst studies to examine the extent of and factors
associated with HPV vaccination occurring in the US after the
recommended ages of 11–12 for routine vaccination. It utilizes a
large sample that is generalizable to the US teen population.
However, there are a few limitations. The household and cellphone
response rate to these surveys were limited [7], which can lead tonon-response/non-coverage bias. Sample weights were utilized to
minimize this bias. In addition, we did not have access to indivi-
duals’ exact birthdays so we were restricted to utilizing ranges for
the ages when the HPV vaccine was approved in June of 2006.
This study suggests that not only does the United States have
incomplete HPV vaccine uptake, but uptake is often occurring at
older ages that can limit the vaccine's population-level effective-
ness. Close to half of HPV vaccinated females are still initiating the
HPV vaccine after the routine-recommended ages of 11–12, par-
ticularly those with a higher social economic status and those not
utilizing healthcare services. Further study is necessary to examine
the population-level impact of later HPV vaccine initiation on
HPV-related outcomes, particularly in these populations.Funding
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